Compliance · patients with treatment of opioid dependence
1 finding from 1 review
Time to recurrence · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT may leads to lower time to disease recurrence compared with WLC TURBT (low certainty).
1 finding from 1 review
Time to progression · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clavien‐Dindo grade ≥ 3 complications · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT showed no clear difference in major adverse event (Clavien‐Dindo grade III, IV, and V) compared with WLC TURBT (low certainty).
1 finding from 1 review
Time to death from bladder cancer · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clavien‐Dindo grade ≤ 2 complications8 · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT showed no clear difference in minor adverse event (Clavien‐Dindo grade I and II) compared with WLC TURBT (low certainty).
1 finding from 1 review
Overall survival (Death) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 diarrhea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 nausea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N+ OS · patients with resectable gastric cancer
The intervention probably leads to lower lymph node mets analysis ‐ N+ OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased OS ‐ 5‐FU based chemotherapy OS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased OS ‐ 5‐FU based chemotherapy OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased OS ‐ Platinum‐based chemotherapy OS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased OS ‐ Platinum‐based chemotherapy OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ 5‐FU based chemotherapy DFS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased DFS ‐ 5‐FU based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ Platinum‐based chemotherapy DFS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased DFS ‐ Platinum‐based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T1/2 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T1/2 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T3/4 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T3/4 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N‐ OS · patients with resectable gastric cancer
The intervention showed no clear difference in lymph node mets analysis ‐ N‐ OS (moderate certainty).
1 finding from 1 review
Time to resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found